US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by PepGen Inc.

< Previous 1 2 Next >
News headline image
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Regulatory Updates on FREEDOM2
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen to Participate in the Leerink Global Healthcare Conference
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Pricing of $100 Million Public Offering
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Proposed Public Offering
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Appointment of Two New Directors to its Board
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1
From PepGen Inc.
Via Business Wire
Tickers PEPG
News headline image
PepGen Announces CONNECT Program Updates
From PepGen Inc.
Via Business Wire
Tickers PEPG
< Previous 1 2 Next >